LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

Kodu・Aktsiate loetelu・Biogen Inc

Biogen Inc

Suletud

Sektor Tervishoid

185.92 0.8

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

182.24

Max

186.42

Põhinäitajad
By Trading Economics
Sissetulek	190M 584M
Müük	180M 2.5B
P/E Sektori keskmine	28.98 112.16
Aktsiakasum	5.28
Kasumimarginaal	23.628
Töötajad	7,570
EBITDA	237M 919M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+43.84 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	30. okt 2024

Turustatistika
By TradingEconomics
Turukapital	-100M 28B
Eelmine avamishind	185.12
Eelmine sulgemishind	185.92

Uudiste sentiment

By Acuity

36%

64%

128 / 390 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

181.31 / 188.59 Toetus ja vastupanu

Biogen Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. sept 2024, 11:00 UTC

Peamised uudised

Pandemic Darling Moderna Needs a Reality Check -- Heard on the Street -- WSJ

29. mai 2024, 15:56 UTC

Tulu

Omandamised, ülevõtmised, äriostud

The Moderna Selloff Gains Steam. An Analyst Has a Few Theories Why. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Biogen Inc Prognoos

Hinnasiht

By TipRanks

43.84% tõus

12 kuu keskmine prognoos

Keskmine 265.6 USD 43.84%

Kõrge 320 USD

Madal 190 USD

Põhineb 22 Wall Streeti analüütiku instrumendi Biogen Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

22 ratings

Osta

Hoia

Müü

Põhineb 22 analüütiku instrumendi Biogen Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

181.31 / 188.59Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

128 / 390 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Biogen Inc

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company's pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.